Skip to main content
. 2021 Aug 11;12:4847. doi: 10.1038/s41467-021-24934-8

Fig. 4. IP6K inhibition decreases the plasma phosphate levels in rats with hyperphosphataemia.

Fig. 4

a Concentration of SC-919 and b plasma phosphate levels following the initial dose of SC-919 or sevelamer in adenine-treated rats. (n = 3 biological replicates for pharmacokinetics and n = 6 and 5 biological replicates for adenine-treated rats and normal rats for determination of phosphate levels in the plasma). c Concentration of SC-919 and d plasma phosphate levels following the seventh dose of SC-919 or sevelamer in adenine-treated rats. (n = 3 biological replicates for pharmacokinetics and n = 6 and 5 biological replicates for adenine-treated rats and normal rats for determination of phosphate levels in the plasma). e Concentration of SC-919 and f plasma phosphate levels in bilaterally nephrectomized rats that were orally administered with SC-919. Animals found dead during the study (1 rat in SC-919 1 mg/kg of e, 2 rats in nephrectomized-vehicle, and 1 rat in nephrectomized-SC-919 1 mg/kg of f. (n = 5–7 biological replicates for nephrectomzed rats, and n = 6 biological replicates for sham-operated rats for e and f). Values indicate mean ± S.D. P < 0.05 and P < 0.05 vs. vehicle as determined using a Williams’ test and the Shirley–Williams test, respectively. Sev sevelamer.